Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Winter Games
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Novo Nordisk pitted a new weight-loss drug against Eli Lilly

Digest more
Top News
Overview
 · 9h · on MSN
Novo Nordisk shares plunge after obesity drug fails to beat Zepbound
The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.

Continue reading

 · 5h
Novo Nordisk's CagriSema Trial Deals Blow in Obesity Drug Battle With Eli Lilly
 · 10h
Novo Nordisk’s New Weight‑Loss Drug Just Failed a Big Trial—So Why Is It Still Headed to Market?
 · 4h
Novo Nordisk’s stock closes at 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial
Novo Nordisk says a study found its experimental next-generation drug didn’t reduce as much weight as Eli Lilly’s Zepbound.

Continue reading

 · 16h
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial
 · 14h
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial -- Update
9hon MSN

Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out

Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
9hon MSN

Why Novo Nordisk Stock Just Crashed

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.
3h

Stocks to Watch Monday Recap: Diamondback, Netflix, Novo Nordisk, Lilly

The telehealth platform said it expects growth to continue this year, though its first quarter guidance [came in short](
5h

Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say

Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim
Pharmaceutical Technology
13h

Novo Nordisk flags board members for re-election amid restructuring efforts

Three new members could join Novo’s council, which largely consists of recent appointees following a restructure in October 2025.
3don MSN

Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board

COPENHAGEN, Feb 20 (Reuters) - Novo Nordisk said on Friday it would nominate Jan van de Winkel and Ramona Sequeira to its board of directors, the first additions since a shake-up at the Danish obesity drugmaker last year.

Related topics

CagriSema
Zepbound
Eli Lilly and Company
Wegovy
  • Privacy
  • Terms